{"id":527222,"date":"2021-01-21T17:36:01","date_gmt":"2021-01-21T17:36:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=527222"},"modified":"2021-01-21T17:36:01","modified_gmt":"2021-01-21T17:36:01","slug":"hyperkalemia-market-analysis-leading-companies-emerging-drugs-and-epidemiology-forecast","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/hyperkalemia-market-analysis-leading-companies-emerging-drugs-and-epidemiology-forecast_527222.html","title":{"rendered":"Hyperkalemia Market Analysis, Leading Companies, Emerging Drugs and Epidemiology Forecast"},"content":{"rendered":"
\"Hyperkalemia<\/a><\/p>\n
\n
Delveinsight Business Research LLP<\/p>\n<\/div>\n<\/div>\n<\/div>\n
DelveInsight’s “Hyperkalemia Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the Hyperkalemia, historical and forecasted epidemiology as well as the Hyperkalemia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n<\/div>\n

Hyperkalemia<\/strong> is defined as the high potassium level in the blood. Potassium helps in the proper functioning of nerves and muscles, including the heart, but too much potassium in the blood can be dangerous and can cause serious heart problems and sudden death. Risk factors for hyperkalemia<\/strong> include several conditions such as chronic kidney disease, diabetes, congestive heart failure and certain medications that disrupt the potassium balance. Also, males are found to suffer more than females with Hyperkalemia.<\/p>\n

Get FREE sample copy at: 
<\/strong>https:\/\/www.delveinsight.com\/sample-request\/hyperkalemia-market<\/strong><\/a><\/p>\n

The Hyperkalemia market report<\/strong> also covers emerging drugs, current treatment practices, <\/span>Hyperkalemia market share of the individual therapies, current and forecasted Hyperkalemia Market Size<\/span> from 2017 to 2030 segmented by seven major markets.<\/span> <\/span><\/p>\n

The report provides a detailed current Hyperkalemia treatment practice\/algorithm<\/strong>, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market. <\/span><\/p>\n

\"Hyperkalemia<\/span><\/p>\n

 <\/p>\n

Hyperkalemia Market Key Facts
<\/strong>According to the National Kidney Foundation, prevalence and incidence of Hyperkalemia<\/strong> have been estimated to be 2-3% in the general population and about 1-10% among hospitalized patients. People with chronic kidney disease, heart failure, diabetes mellitus, and those taking blood pressure medicines (RAASi) have an estimated 2–3 times higher risk for hyperkalemia. More than half of pre-dialysis CKD patients are at risk of developing Hyperkalemia.<\/p>\n

In a study conducted by Betts et al. (2018), it was estimated that the annual prevalence of hyperkalemia<\/strong> was 1.57% in 2014, with higher rates observed in patients with chronic kidney disease (CKD), heart failure, diabetes, and hypertension. Among patients with CKD and\/or heart failure, the 2014 annual prevalence was 6.35%.<\/p>\n

Key Benefits of Hyperkalemia Market Report<\/span><\/strong><\/p>\n